Skip to content

Effect of Prostate24 in prostate enlargement

An open-labelled, prospective clinical study to evaluate effect of Prostate24 in benign prostatic hyperplasia male human patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/10/046400
Enrollment
15
Registered
2022-10-12
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms

Interventions

Intervention1: Prostate24: Prostate24, 400 mg capsule (oral), twice a day for 60 days Control Intervention1: Not applicable: Not applicable

Sponsors

Institute of Pharmacy Nirma University
Lead Sponsor
Probiotic Smart LLC
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: i. Age above 45 years ii. Male participants diagnosed with BPH iii. Participant must not have taken any drug/ vitamin/ mineral/ dietary or herbal supplements for BPH 1 month prior to enrolment in the study and agrees to not use any new vitamins and/or minerals and/or dietary and/or herbal supplements until after study completion. iv. Participant must be able, willing and likely to fully comply with study procedures and restrictions. v. Participant willing to sign the informed consent

Exclusion criteria

Exclusion criteria: i. Evidence of renal disease (S. Creatinine > 1.5mg/ml) ii. Evidence of liver disease (AST/ALT >3 times of normal) iii. History of alcohol intake and smoking. iv. Participation in any other clinical trial with in the last 30 days v. History of intake of diuretics, Finasteride like drugs or dietary supplements for the treatment of BPH vi. History of intolerance or hypersensitivity to any of the content of the study drug vii. Any condition which in the opinion of the PI that is significant and can make the subject unsuitable for study or can place it under additional risk, such as intolerance, allergy to study drug, etc

Design outcomes

Primary

MeasureTime frame
Mean percent changes in the overall signs and symptoms of BPH after the treatment with Prostate24 from baseline to 60 days. These will include, � Physical examination and DRE � PSA � CRP � Sr. Creatinine Timepoint: 0, 30, 60 day

Secondary

MeasureTime frame
To assess the adverse drug reactions of Prostate24Timepoint: 0, 30, 60 day

Countries

India

Contacts

Public ContactShital Sharadkumar Panchal

Institute of Pharmacy Nirma University

shital.panchal@nirmauni.ac.in9687626589

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026